Merck & Co. Inc., of Kenilworth, N.J., said The Lancet and Clinical Infectious Diseases have published online the results from the pivotal phase III studies of Zerbaxa (ceftolozane/tazobactam) for injection (1 g/0.5 g) in complicated urinary tract infections and complicated intra-abdominal infections, respectively.